Every material Form 8-K Viking Therapeutics, Inc. has filed with the SEC since September 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Viking Therapeutics reported a third-quarter 2026 net loss of $183.2 million, or $1.55 per share, up from $90.8 million, or $0.81 per share, a year earlier, with no revenue in either period. Research and development expenses rose to $166.8 million from $90.0 million, and the company ended the quarter with $960 million in cash, cash equivalents and short-term investments after September stock and convertible note offerings, which shareholders should weigh against the higher spending.
Q3 2026 net loss of $183.2 million ($1.55 per share) versus $90.8 million ($0.81 per share) in Q3 2025
Research and development expenses of $166.8 million, up from $90.0 million; general and administrative expenses of $20.3 million, up from $8.6 million
Cash, cash equivalents and short-term investments of $960 million at September 30, 2026, versus $706 million at December 31, 2025
Positive top-line maintenance study results for VK2735 announced in the quarter; VANQUISH Phase 3 trials expected to complete in 2027
Viking Therapeutics sold 7,857,143 shares of common stock at $35.00 per share and separately sold $225.0 million of 2.00% convertible senior notes due 2032, with underwriters exercising their options in full. Net proceeds were about $297.0 million from the stock sale and about $250.8 million from the notes, which the company intends to use for its VK2735 and VK3019 programs and general corporate purposes. The stock sale adds shares outstanding for existing shareholders, and the notes add debt that could convert into common stock at about $50.75 per share.
Stock: 7,857,143 shares at $35.00 per share, plus 1,178,571 option shares exercised in full on September 24, 2026; closed September 25, 2026; net proceeds about $297.0 million
Notes: $225.0 million of 2.00% convertible senior notes due October 15, 2032, plus a $33,750,000 option exercised in full on September 24, 2026; net proceeds about $250.8 million
Conversion price about $50.75 per share (19.7044 shares per $1,000 principal); company may settle conversions in cash, shares or a combination
Proceeds intended for VK2735 and VK3019 clinical programs and general corporate purposes
Viking Therapeutics reported positive topline results from the maintenance phase of its VK2735 study, in which patients moved to every-other-week or monthly dosing maintained up to 97% and up to 90% of their weight loss, respectively. The company also reported GI-related adverse event rates similar to placebo, and the filing presents no financial measures for the period.
Every-other-week dosing maintained up to 97% of Week 21 weight loss versus 61% for placebo (p<0.0001).
Monthly dosing maintained up to 90% of Week 21 weight loss versus 61% for placebo (p=0.0002).
Induction phase: weight loss of approximately 16% to 19% after 21 weeks of weekly dosing versus approximately 0% for placebo.
Management conference call scheduled for 8:00 a.m. ET on September 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Viking Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →